Skip to main content

Table 2 Description of the baseline characteristics of the patients in the different studies included in the meta-analysis

From: Screening for asymptomatic coronary artery disease in patients with diabetes mellitus: A systematic review and meta-analysis of randomized trials

  Faglia et al. (2005) DIAD (2009) DYNAMIT (2011) FACTOR-64 (2014) DADDY-D (2015)
Number of patients      
 - Screening 71 561 316 452 262
 - Control 70 562 315 447 258
Age, y ± SD      
 - Screening 58.7 ± 8.3 60.7 ± 6.7 64.1 ± 6.4 61.5 ± 7.9 61.9 ± 4.8
 - Control 61.5 ± 8.1 60.8 ± 6.4 63.7 ± 6.4 61.6 ± 8.4 62.0 ± 5.1
BMI, kg/m2 ± SD      
 - Screening 27.2 ± 5.1 31.1 ± 6.5 30.4 + 4.7 32.9 ± 6.8 29.6 ± 4.9
 - Control 28.3 ± 4.6 31.0 + 6.1 30.8 ± 5.3 33.4 ± 7.1 30.6 ± 7.2
Women      
 - Screening 39 % 48 % 45 % 48 % 20 %
 - Control 47 % 45 % 46 % 47 % 20 %
Smokersa      
 - Screening 65 % 10 % 17 % 17 % 40 %
 - Control 79 % 9 % 15 % 15 % 38 %
Systolic BP, mmHg ± SD      
 - Screening 143 ± 19 133 ± 17 129 ± 12 140 ± 15
 - Control 142 ± 17 132 ± 16 131 ± 11 141 ± 15
Diastolic BP, mmHg ± SD      
 - Screening 86 ± 11 80 ± 9 74 ± 8 82 ± 7
 - Control 84 ± 10 79 ± 8 74 ± 8 81 ± 7
LDL-C, mg/dL ± SD      
 - Screening 114 ± 32 86 ± 29 125 ± 37
 - Control 114 ± 33 88 ± 33 119 ± 33
HDL-C, mg/dL ± SD      
 - Screening 49 ± 15 50 ± 15 45 ± 14 42 ± 11
 - Control 46 ± 15 49 ± 15 45 ± 13 42 ± 12
Triglycerides, mg/dL ± SD or [95 % CI]      
 - Screening 154 ± 105 172 ± 118 144 [99–201] 163 ± 140
 - Control 161 ± 88 168 ± 101 132 [92–198] 161 ± 96
Type 2 diabetes      
 - Screening 100 % 100 % 100 % 88 % 100 %
 - Control 100 % 100 % 100 % 88 % 100 %
Duration of DM, y ± SD      
 - Screening 11.6 ± 10.6 8.2 ± 7.1 12.3 ± 9.2 9.9 ± 6.7
 - Control 11.3 ± 10.3 8.9 ± 6.9 13.5 ± 10.7 10.0 ± 6.2
Insulin      
 - Screening 11 % 24 % 43 % 23 %
 - Control 14 % 22 % 43 % 21 %
HbA1c, % ± SD      
 - Screening 8.6 ± 2.3 7.2 ± 1.6 8.6 ± 2.2 7.4 ± 1.4 7.7 ± 1.4
 - Control 8.4 ± 1.9 7.0 ± 1.5 8.7 ± 2.0 7.5 ± 1.4 7.8 ± 3.1
Retinopathy      
 - Screening 56 % 14 % 14 %
 - Control 59 % 16 % 17 %
Peripheral vascular disease      
 - Screening 9 % 14 % 5 %
 - Control 9 % 14 % 7 %
Statins use (baseline)      
 - Screening 39 % 37 % 77 % 49 %
 - Control 30 % 41 % 72 % 44 %
Aspirin use (baseline)      
 - Screening 13 % 43 % 43 % 29 %
 - Control 17 % 46 % 41 % 26 %
ACE/ARB use (baseline)      
 - Screening 14 % 37 % 62 %
 - Control 14 % 41 % 65 %
  1. ACE/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, BMI body-mass index, BP blood pressure, CI confidence interval, DM diabetes mellitus, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
  2. adata are for smokers in Faglia et al. and DYNAMIT, current smokers in DIAD and DADDY-D, former or current smokers in FACTOR-64